Search

Your search keyword '"Bulina I"' showing total 38 results

Search Constraints

Start Over You searched for: Author "Bulina I" Remove constraint Author: "Bulina I"
38 results on '"Bulina I"'

Search Results

1. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

2. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

3. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET

4. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

5. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products.

6. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

7. Rare clinical manifestations in systemic lupus erythematosus: A review on frequency and clinical presentation

8. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

9. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases:insights after the first 5 years of the ERN ReCONNET

10. POS1212 SARS-CoV-2 VACCINE SAFETY IN ADOLESCENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES AND ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS

12. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

26. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

27. The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET

28. Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.

29. Prevalence and gender - specific analysis of a systemic sclerosis cohort in Latvia.

30. Obstetric outcomes in women with rheumatic disease and COVID-19 in the context of vaccination status.

31. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products.

32. An overlook on the current registries for rare and complex connective tissue diseases and the future scenario of TogethERN ReCONNET.

33. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

34. SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry.

35. Rare clinical manifestations in systemic lupus erythematosus: a review on frequency and clinical presentation.

36. COVID-19 vaccine perceptions and uptake: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey.

37. SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry.

38. Neuroinflammatory Disease as an Isolated Manifestation of Hemophagocytic Lymphohistiocytosis.

Catalog

Books, media, physical & digital resources